Gene therapy injection aims to tame Parkinson's symptoms

NCT ID NCT07566429

Not yet recruiting Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests a single injection of AB-1005 gene therapy directly into the brain for Japanese adults with moderate Parkinson's disease. The goal is to see if it is safe and can improve daily movement. Eight participants will be followed for 18 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Juntendo University Hospital - Neurology

Bunkyo-ku, Tokyo, 113-8431, Japan
Nagoya Central Hospital - Neurosurgery

Nagoya, Aichi-ken, 453-0801, Japan
Nagoya University Hospital - Neurology

Nagoya, Aichi-ken, 466-8560, Japan
National Hospital Organization Osaka Toneyama Medical Center - Neurology

Toyonaka, Osaka, 560-8552, Japan
National Hospital Organization Utano National Hospital - Neurology

Kyoto, 616-8255, Japan
Yokohama City University Medical Center - Neurology

Yokohama, Kanagawa, 232-0024, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.